



	Dr. Vinay Che MD (Pathology & Chairman & Cons	Microbiology)	Dr. Yugam MD CEO & Consultant	(Pathology)	
IAME	: Mr. RAKESH				
AGE/ GENDER	: 39 YRS/MALE	PATIE	INT ID	: 1817503	
COLLECTED BY	:	REG. N	IO./LAB NO.	: 012504040019	
REFERRED BY			TRATION DATE	: 04/Apr/2025 10:18 AM	
BARCODE NO.	: 01528334		ECTION DATE	: 04/Apr/2025 10:19AM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB		RTING DATE	1	
			KIING DATE	: 04/Apr/2025 12:24PM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	AMBALA CANTT			
Test Name		Value	Unit	Biological Reference interval	
GLYCOSYLATED HAEMOGLOBIN (HbA1c): WHOLE BLOOD by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) ESTIMATED AVERAGE PLASMA GLUCOSE by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) INTERPRETATION:		82.45	mg/dL	60.00 - 140.00	
	AS PER AMERICAN	DIABETES ASSOCIATION (ADA):		
	REFERENCE GROUP		GLYCOSYLATED HEMOGLOGIB (HBAIC) in %		
Non diabetic Adults >= 18 years		<5.7			
	At Risk (Prediabetes)		5.7 - 6.4		
А			>= 6.5		
А	iagnosing Diabetes				
A		Coals of Tho	Age > 19 Years	< 7.0	
A D	iagnosing Diabetes	Goals of The	Age > 19 Years	< 7.0	
A D		Goals of The Actions Sugge	Age > 19 Years	< 7.0 >8.0	

concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropiate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



TEST PERFORMED AT KOS DIAGNOSTIC LAB. AMBALA CANTT



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



KOS Diagnostic Lab (A Unit of KOS Healthcare)

		Dr. Vinay Ch MD (Pathology & Chairman & Cor			(Pathology)
NAME	: Mr. RAKESI		nsultant Pathologis	t CEO & Consultant	Pathologist
AGE/ GENDER	: 39 YRS/MAL	E		PATIENT ID	: 1817503
COLLECTED BY	:			REG. NO./LAB NO.	: 012504040019
REFERRED BY	:			REGISTRATION DATE	: 04/Apr/2025 10:18 AM
BARCODE NO.	:01528334			COLLECTION DATE	:04/Apr/2025 10:19AM
LIENT CODE.	: KOS DIAGNO	OSTIC LAB		REPORTING DATE	: 04/Apr/2025 11:52AM
LIENT ADDRESS	: 6349/1, NIC	CHOLSON ROAD,	AMBALA CANTT		
Fest Name			Value	Unit	Biological Reference interval
		CLINIC	AL CHEMIS	STRY/BIOCHEMIS	TRY
		CLINE		E FASTING (F)	
GLUCOSE FASTIN			98.53	mg/dL	NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0 DIABETIC: > 0R = 126.0
		2	*** End Of Re	eport ***	
		,	*** End Of Re	eport ***	
		,	*** End Of Re	eport ***	
			*** End Of Re	eport ***	
			*** End Of Re	eport ***	
			*** End Of Re	eport ***	
			*** End Of Re	eport ***	
			*** End Of Re	eport ***	
			*** End Of Re	eport ***	
			*** End Of Re	eport ***	
			*** End Of Re	eport ***	

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

099937

673

